PMV Pharmaceuticals (PMVP) CFO receives 240,000-share stock option grant

Q: What insider transaction did PMV Pharmaceuticals (PMVP) report for Michael Carulli?

PMV Pharmaceuticals reported that CFO Michael Carulli received an employee stock option grant for 240,000 shares on March 5, 2026 . The option is an equity compensation award with an exercise price of $0.00 per share, classified as a grant or award acquisition.

Q: How do the new stock options for PMVP’s CFO vest over time?

The 240,000-share option granted to PMVP’s CFO vests in 48 equal monthly installments starting on April 5, 2026. This creates a four-year vesting schedule, with a portion of the award becoming exercisable each month, aligning compensation with long-term company performance.

Q: What does the Form 4 say about PMVP CFO’s Employee Stock Purchase Plan shares?

The Form 4 states that the CFO’s holdings include 13,702 shares acquired under PMV Pharmaceuticals’ Employee Stock Purchase Plan on November 20, 2025. These ESPP shares are part of his 73,848 directly owned common shares reported after the latest transactions.

Q: Was there any sale of PMV Pharmaceuticals (PMVP) shares by the CFO in this Form 4?

The Form 4 shows an option grant of 240,000 shares to the CFO and updated holdings, but no reported share sales . The main coded transaction is a grant, categorized as a grant or award acquisition, not a disposition or open-market sale.

Q: What is the exercise price of the new PMVP stock options granted to the CFO?

The newly granted employee stock option for 240,000 shares of PMV Pharmaceuticals common stock has an exercise price of $0.00 per share. This indicates a cost-free grant structure for the award itself, subject to the four-year monthly vesting schedule.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. Chief Financial Officer Michael Carulli reported an equity compensation grant and updated his share holdings. He received an employee stock option for 240,000 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.

The option vests in 48 equal monthly installments beginning on April 5, 2026, which means the award vests gradually over four years. Following this filing, Carulli directly holds 73,848 shares of common stock, which includes 13,702 shares acquired under the company’s Employee Stock Purchase Plan on November 20, 2025.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Carulli Michael

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	240,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 240,000 shares (Direct); Common Stock — 73,848 shares (Direct)

Footnotes (1)

Includes 13,702 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025. Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

Form 4 Insider Transactions: What Each Field Means →

03/09/2026 - 04:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carulli Michael

(Last)

(First)

(Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON

08540

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								73,848⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$1.53	03/05/2026		A		240,000		⁽²⁾	03/05/2036	Common Stock	240,000	$0	240,000	D

Explanation of Responses:

1. Includes 13,702 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025.

2. Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

	/s/ Robert Ticktin, by power ot attorney	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PMV Pharmaceuticals (PMVP) report for Michael Carulli?

PMV Pharmaceuticals reported that CFO Michael Carulli received an employee stock option grant for 240,000 shares on March 5, 2026. The option is an equity compensation award with an exercise price of $0.00 per share, classified as a grant or award acquisition.

How do the new stock options for PMVP’s CFO vest over time?

The 240,000-share option granted to PMVP’s CFO vests in 48 equal monthly installments starting on April 5, 2026. This creates a four-year vesting schedule, with a portion of the award becoming exercisable each month, aligning compensation with long-term company performance.

How many PMV Pharmaceuticals (PMVP) common shares does the CFO hold after this filing?

After the reported transactions, PMV Pharmaceuticals’ CFO directly holds 73,848 shares of common stock. This total includes 13,702 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025, as disclosed in the Form 4 footnotes.

What does the Form 4 say about PMVP CFO’s Employee Stock Purchase Plan shares?

The Form 4 states that the CFO’s holdings include 13,702 shares acquired under PMV Pharmaceuticals’ Employee Stock Purchase Plan on November 20, 2025. These ESPP shares are part of his 73,848 directly owned common shares reported after the latest transactions.

Was there any sale of PMV Pharmaceuticals (PMVP) shares by the CFO in this Form 4?

The Form 4 shows an option grant of 240,000 shares to the CFO and updated holdings, but no reported share sales. The main coded transaction is a grant, categorized as a grant or award acquisition, not a disposition or open-market sale.

What is the exercise price of the new PMVP stock options granted to the CFO?

The newly granted employee stock option for 240,000 shares of PMV Pharmaceuticals common stock has an exercise price of $0.00 per share. This indicates a cost-free grant structure for the award itself, subject to the four-year monthly vesting schedule.